The available evidence indicates that camelid VHH represent a highly versatile and adaptable platform for antiviral therapeutics and diagnostics, with considerable potential to support pandemic preparedness and the development of broad-spectrum interventions against current and emerging viral diseases.
Abstract
Viral infections continue to pose a major global health challenge because of rapid viral evolution, immune escape, and the emergence of novel pathogens. This review examines the biological characteristics, antiviral mechanisms, production strategies, and therapeutic potential of camelid VHH as next-generation antiviral agents. The review synthesizes current evidence on the structural and functional properties of VHH, their methods of generation and engineering, and their applications against a broad range of respiratory and non-respiratory viruses. Camelid VHH nanobodies exhibit high specificity and affinity, exceptional physicochemical stability, efficient tissue penetration, and the unique ability to recognize conserved and cryptic epitopes that are often inaccessible to conventional antibodies. Engineering approaches, including multivalent, bispecific, Fc-fused, and half-life-extended constructs, further enhance their antiviral potency and pharmacokinetic properties. Evidence from preclinical studies demonstrates potent antiviral activity against multiple viral pathogens through mechanisms that include blocking viral attachment and fusion, inhibiting intracellular replication, targeting conserved viral proteins, and reducing the likelihood of viral escape. The review also highlights emerging advances in recombinant production platforms, artificial intelligence-assisted nanobody design, targeted delivery technologies, and One Health applications. Collectively, the available evidence indicates that camelid VHH represent a highly versatile and adaptable platform for antiviral therapeutics and diagnostics, with considerable potential to support pandemic preparedness and the development of broad-spectrum interventions against current and emerging viral diseases.
Camelid variable heavy-chain (VHH) nanobodies have emerged as a promising class of single-domain antibodies with significant potential for combating bacterial and parasitic infections. Their small molecular size, high solubility, exceptional physicochemical stability, and ability to recognize cryptic or conformational...
H. Gattan, T. Alandijany· Frontiers in Immunology· 0 citations
It is demonstrated that nanobodies targeting the PLpro/ISG15 interface can achieve synergistic antiviral and immunomodulatory effects, providing a proof-of-concept for a novel therapeutic approach to combat SARS-CoV-2 and potentially other emerging coronaviruses.
Guo-Long Liu, Jian-Tao Chen, Fang Wu et al.· Journal of Virology· 0 citations
This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets.
S. K. Samrat, Gaurie Srivastava, Ran Zhang et al.· Pathogens· 0 citations
F4-Fc demonstrates prophylactic and therapeutic efficacy against influenza A and B viruses, representing a promising antiviral drug candidate for influenza virus infection and demonstrating its antiviral efficacy in vitro and protective activity in vivo.
Dong-Lan Liu, Yuxuan Zhang, Min Zhang et al.· Journal of Virology· 0 citations
INTRODUCTION
Viruses pose serious threats to public health, with frequent outbreaks of emerging and reemerging viral pathogens. Given the limitations of current antiviral therapies, the search for new control strategies is essential. In this context, chalcones have attracted great attention due to their structural vers...
Leonardo Dos Santos Corrêa Amorim, N. C. da Rocha, K. F. C. de Souza E Souza et al.· Mini-Reviews in Medical Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.